Private equity giant KKR & Co Inc said on Tuesday it will buy Japanese drug developer Bushu Pharmaceuticals from Hong Kong-based private equity firm BPEA EQT, but did not disclose financial details of the deal.
KKR said in a press statement it aims to expand Bushu Pharma into new as well as growth segments such as injectables, invest in further capacity expansion and quality control, and seek further growth opportunities.
The investment firm said it sees significant demand for strategic and reliable solutions to address challenges facing the healthcare industry, and aims to push the Japanese firm to further scale its business.
Read more: Reuters
